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Abstract
Background: Interleukins and cytokines play an important role in the pathogenesis of many solid
cancers. Several single nucleotide polymorphisms (SNPs) identified in cytokine genes are thought
to influence the expression or function of these proteins and many have been evaluated for their
role in inflammatory disease and cancer predisposition. The aim of this study was to evaluate any
role of specific SNPs in the interleukin genes IL1A, IL1B, IL1RN, IL4R, IL6 and IL10 in predisposition
to breast cancer susceptibility and severity.
Methods:  Candidate single nucleotide polymorphisms (SNPs) in key cytokine genes were
genotyped in breast cancer patients and in appropriate healthy volunteers who were similar in age,
race and sex. Genotyping was performed using a high throughput allelic discrimination method.
Data on clinico-pathological details and survival were collected. A systematic review of Medline
English literature was done to retrieve previous studies of these polymorphisms in breast cancer.
Results: None of the polymorphisms studied showed any overall predisposition to breast cancer
susceptibility, severity or to time to death or occurrence of distant metastases. The results of the
systematic review are summarised.
Conclusion: Polymorphisms within key interleukin genes (IL1A, IL1B, IL1RN, IL4R, IL6 and IL10
do not appear to play a significant overall role in breast cancer susceptibility or severity.
Background
The role of cytokines in cancer immunity and carcinogen-
esis in general has been well established [1]. Single
nucleotide polymorphisms in specific candidate genes are
thought to influence expression and/or activity of the
encoding proteins thereby predisposing to solid cancers
especially breast cancer [2]. Many cytokine polymor-
phisms have been studied for associations with suscepti-
bility to gastric cancer [3-5], liver cancer [6,7], lung
cancer[8], prostate cancer [9] and ovarian cancer [10] with
mixed results.
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The cytokines of the IL-1 family [11], IL-4 and its receptor
[12,13], IL-6 [14,15] and IL-10 [16,17] are important can-
didate genes as they play an important role in breast can-
cer pathogenesis. IL1-alpha promotes growth of breast
cancer cells and cachexia [18]. In breast cancer cells, IL1-
beta increases the transcriptional activity of ER-alpha [19]
which is a prognostic factor in breast cancer and the
expression and stabilisation of IL-8 RNA [20] which is a
potent angiogenic factor. IL-4 inhibits tumour growth by
its anti-angiogenic effect [21] and inhibits growth and
induces apoptosis of breast cancer cell lines in the pres-
ence of IL-4R [12]. Circulating IL6 levels have been found
to be higher in breast cancer patients compared to healthy
controls and among those with breast cancer, correlate
with the stage of the disease [14]. IL10 is over expressed in
breast tumours [16] and exogenous administration can
mediate regression of tumour growth and breast cancer
metastases in mice models [17].
The polymorphisms studied were selected in the light of
previous reports of their effect on differential gene expres-
sion and/or disease susceptibility. The IL1A +4845 G>T
polymorphism situated in exon 5 of the IL1A gene was
described in 1993 [22] and results in an Ala to Ser amino
acid substitution at residue 114 of the proIL1α molecule.
Pro IL1α is cleaved between amino acids 112 and 113 and
it has been suggested that this polymorphism may affect
the proteolytic process [23]. The polymorphism is
thought to influence C reactive protein levels in patients
referred for coronary angiography [24] and influence the
development of aggressive periodontitis in Chinese males
[25]. Three polymorphisms commonly studied in the
IL1B gene include -511 and -31 in the promoter region
and the +3954 in exon 5, all representing a C>T single
nucleotide change. The -511C>T and the +3954C>T SNPs
are thought to influence C reactive protein levels in
healthy individuals [26] and the +3954C>T polymor-
phism has been shown to influence IL1β production by
monocytes in vitro [27]. The -511 polymorphism has been
shown to be associated with vascular diseases such as
stroke [28] and along with the +3954 polymorphisms has
been extensively studied in gastric cancer [29-31]. The
IL1RN +2018T>C polymorphism in exon 2 of the gene is
in complete linkage disequilibrium with a penta-allelic 86
bp variable number of tandem repeat polymorphism in
intron 2 of the gene which is strongly linked to increased
production of IL1RA [32] and IL1β  in vitro [33]. The
penta-allelic polymorphism has been studied in several
cancers including gastric cancer [29-31], lung cancer [34],
ovarian cancer [35] and cervical cancer [36]. The +2018
SNP itself has been linked with Barrett's oesophagus and
oesophageal cancer [37]. The IL4R 1902A>G polymor-
phism is an A to G transition at nucleotide 1902, causing
a change in amino acid from glutamine to arginine at
codon 576 in the interleukin-4 receptor alpha protein.
This seems to alter the signalling function of the receptor,
thereby predisposing carriers to disease [38]. Preliminary
studies show some association of this polymorphism with
Crohn's disease [39] and adult asthma [40]. The polymor-
phism has also been associated with an increased risk of
renal cancer [41]. The IL6 -174G>C polymorphism in the
5' flanking region of the gene was initially reported in
1998 to influence IL6 expression and plasma levels (the -
174C allele associated with lower expression and lower
levels) [42]. Subsequent studies of this polymorphism
show that the -174C allele decreases susceptibility to sys-
temic juvenile idiopathic arthritis [43] and increases the
risk of coronary artery disease presumably through
inflammatory mechanisms [44,45]. It also has been
shown to increase the risk of bladder cancer [46], colorec-
tal cancer [47] and Kaposi's sarcoma in HIV infected men
[48]. The IL10 -1082G>A polymorphism, situated in the
promoter region of the gene, has been shown to influence
IL10 protein production in vitro by concanavalin-A stimu-
lated peripheral mononuclear cells [49]. The G allele is
associated with an increased risk of Crohn's disease [50]
and thought to increase predisposition to lung cancer
[51]. The AA genotype has been shown to be associated
with decreased survival in melanoma [52].
The aim of this study was to evaluate polymorphisms in
specific cytokine genes [IL1A +4845G>T, IL1B -511C>T,
IL1B +3954C>T, IL1RN +2018T>C, IL4R -1902A>G, IL6-
174G>C and IL10-1082G>A] in a case control model to
determine any associations with breast cancer susceptibil-
ity, severity and survival. A systematic review of the Eng-
lish language Medline literature through PubMed was
performed to summarise all previous breast cancer related
studies of the polymorphisms characterised in the current
study.
Methods
Case-control study
The design and methodology of this case control study
have previously been described [53,54]. Briefly, recruit-
ment started in November 1998 and is ongoing. The cases
include women diagnosed with breast cancer and being
followed up at the Royal Hallamshire Hospital in Shef-
field and Rotherham District General Hospital and con-
trols were recruited from women attending the Sheffield
Breast Screening Service. The study was restricted to white
Caucasians, as there were insufficient individuals from
other ethnic groups, for meaningful analysis. The South
Sheffield Research Ethics Committee approved the study
[Ref. no. SS98/137] and informed written consent was
obtained from all subjects. Demographic, environmental
risk factors and family history data were recorded for all
breast cancer cases and mammography screening con-
trols, using a standard questionnaire. Pathological data
(including tumour grade, lymph node status and presenceBMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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of vascular invasion) were obtained from medical records
and validated by an experienced histopathologist (SSC).
Data on disease recurrence and overall survival were
obtained from the hospital records and the Trent Cancer
Registry. The data was entered by trained personnel and
stored in a Microsoft Access database and maintained by
a dedicated database administrator. The data was vali-
dated for all the records (by SPB and database manager).
Genotyping methods
Genomic DNA was extracted from frozen EDTA preserved
peripheral venous blood from all individuals, as
described previously [55]. The polymorphisms studied,
along with the genes, location and unique ID is shown in
Table 1. Genotyping of the polymorphisms was per-
formed by the 5'nuclease PCR method, using the ABI/PE
Biosystems Taqman™ system, essentially as described ear-
lier [55]. Using specific primer and probe sequences
(Table 1), PCR amplification was carried out separately
for the different polymorphisms. The final concentrations
of the different constituents of the PCR mixture and the
cycling temperatures for the various SNPs studied are
shown in Tables 2 and 3. Levels of FAM and TET fluores-
cence were determined and allelic discrimination was car-
ried out using the ABI 7200 Sequence Detector. Quality
control for the genotyping results was achieved by using
only 72 of the 96 wells in each of the plates for the indi-
vidual DNA samples subjected to PCR. Six to eight wells
were allotted to 'no sample' controls, 'common
homozygous' controls and 'rare homozygous' controls
each, in addition to retesting of samples with indetermi-
nate results. The common and rare homozygous controls
included samples tested before and shown to be 'common
homozygous' and 'rare homozygous' respectively.
Methodology for systematic review
A Medline search was conducted on 26th September 2005
with the following search strategy: (("interleukins"[TIAB]
NOT Medline [SB]) OR "interleukins"[MeSH Terms] OR
interleukin[Text Word]) OR (("cytokines"[TIAB] NOT
Medline[SB]) OR "cytokines"[MeSH Terms] OR
cytokine[Text Word]) AND ("genetic polymor-
phism"[Text Word] OR "polymorphism, genetic"[MeSH
Terms] OR polymorphism[Text Word]) OR SNP[All
Table 2: Final concentration of the different constituents of the PCR mixture
PCR constituents Final concentrations for the various SNPs
IL1A +4845 IL1B -511 IL1B +3954 IL1RN +2018 IL4R +1902 IL6 -174 IL10 -1082
Taqman mastermix (2X) 1X 1X 1X 1X 1X 1X 1X
Forward primer (10 μM) 500 nM 100 nM 300 nM 250 nM 50 nM 50 nM 50 nM
Reverse primer (10 μM) 500 nM 100 nM 300 nM 250 nM 500 nM 50 nM 300 nM
FAM probe (5 μM) 50 nM 50 nM 50 nM 30 nM 30 nM 30 nM 50 nM
TET probe (5 μM) 100 nM 100 nM 75 nM 150 nM 120 nM 60 nM 150 nM
Template (20 ng/μl) 0.8 ng/μl 0.8 ng/μl 0.8 ng/μl 0.8 ng/μl 0.8 ng/μl 0.8 ng/μl 0.8 ng/μl
Taqman mastermix: Universal PCR mastermix (PE Biosystems) containing MgCl2, dNTPs, Taq polymerase, optimised buffer components and Rox 
reference dye; FAM probe: 6-carboxy-fluorescein-labelled probe; TET: 6-carboxy-4,7,2',7'-tetrechlorofluorescein-labelled probe.
Table 1: Candidate single nucleotide polymorphisms (SNPs) and their respective probes and primers
Gene Location SNP ID Forward primer Reverse primer FAM probe TET probe
IL-1A +4845 G>T rs17561 TGCACTTGTGATCAT
GGTTTTAGA
TCCTCATAAAGTTGT
ATTTCACATTGC
CAAGCCTAGGTCATC
ACCTTTTAGCTTCC
AAGCCTAGGTCAGCA
CCTTTTAGCTTCC
IL-1B -511 C>T rs16944 TTGAGGGTGTGGGTC
TCTACCT
AGGAGCCTGAACCCT
GCATAC
TTCTCTGCCTCGGGA
GCTCTCTGT
TTCTCTGCCTCAGGA
GCTCTCTGTCA
IL-1B +3954 C>T rs1143634 GCCTGCCCTTCTGAT
TTTATACC
CATCGTGCACATAAG
CCTCGTTA
TTCAGAACCTATCTT
CTTTGACACATGGGA
CAGAACCTATCTTCT
TCGACACATGGGA
IL-1RN +2018 T>C rs419598 GGGATGTTAACCAGA
AGACCTTCTATCT
CAACCACTCACCTTC
TAAATTGACATT
AACAACCAACTAGTT
GCTGGATACTTGCAA
ACAACCAACTAGTTG
CCGGATACTTGC
IL-4R +1902 A>G rs1801275 AGGCTTGAGAAGGC
CTTGTAA
CCGAAATGTCCTCCA
GCAT
CATGTACAAACTCCT
GATAGCCACTGGTG
CATGTACAAACTCCC
GATAGCCACTGG
IL-6 -174 G>C rs1800795 GCTGATTGGAAACCT
TATTAAGATTGT
AATGACGACCTAAGC
TGCACTTT
ACGTCCTTTAGCATC
GCAAGACACAAC
ACGTCCTTTAGCATG
GCAAGACACAAC
IL-10 -1082 G>A rs1800896 GATAGGAGGTCCCTT
ACTTTCCTCTTA
CACACACAAATCCAA
GACAACACTAC
CTACTTCCCCCTCCC
AAAGAAGCCT
CCTACTTCCCCTTCC
CAAAGAAGCC
Note: All sequences are from 5' end to 3' end.BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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Fields] AND (("neoplasms"[TIAB] NOT Medline[SB]) OR
"neoplasms"[MeSH Terms] OR cancer[Text Word]) AND
English[Lang]. Only articles on the polymorphisms evalu-
ated in this study were included for the purposes of the
review and their results are summarised in the discussion.
Data processing and analysis
All data were entered initially into a Microsoft Access data-
base and exported to SPSS (version 12.0.1 for Windows)
for statistical analyses. Chi-square test for trend was per-
formed to compare the genotype frequencies (1:1, 1:2 and
2:2 representing the common homozygous, heterozygous
and the rare heterozygous respectively) between cases and
controls and also for comparison of the genotype frequen-
cies among the various subgroups of breast cancer. Kaplan
Meier curves and the log rank test was used for the survival
analyses. All tests were two sided. Haplotype analysis was
then performed on the genotype data of the four polymor-
phisms (IL1A +4845G>T, IL1B +3954C>T, IL1B -511C>T
and IL1RN +2018T>C) in chromosomal region 2q13
using Haploview [56].
Results
The demographic characteristics and comparability of
case and control cohorts have been reported previously
[53,54]. Briefly, the case and control groups were all Cau-
casian and female. There were no significant differences in
the percentage of postmenopausal women, age at
menarche and age at menopause between the cancer and
control groups. The women in the control groups were
however younger [median (IQR) of 57 (53–61) in the
control group vs. 63 (54–70) in the cancer group; p <
0.001; Mann-Whitney U test], were younger when first
pregnant [median (IQR) of 23 (20–26) in the control
group vs. 24 (21–27) in the cancer group; p < 0.001;
Mann-Whitney U test], had more children [median (IQR)
of 2 (2–3) in the control group vs. 2 (1–3) in the cancer
group; p < 0.001; Mann-Whitney U test], were less likely
to have a family history of breast cancer [22.2% in con-
trols vs. 27.4% in cancers; p = 0.007; Chi-square test] and
were more likely not to have smoked [63.1% in controls
vs. 53.4% in cancers; p < 0.001; Chi-square test].
Table 4 shows the total numbers, the observed frequencies
and the expected genotype frequencies (expected geno-
type frequencies were calculated from the respective allele
frequencies) in the control population and the testing for
the Hardy Weinberg Equilibrium. The observed frequen-
cies of the genotypes for all polymorphisms are not signif-
icantly different from the expected frequencies except for
the IL1A +4845 and the IL4R +1902 polymorphisms.
The comparison of genotype frequencies between the con-
trol and cancer groups for each of the polymorphisms
(along with the actual numbers studied) are shown in
Table 5. In addition to overall comparisons, the genotype
frequencies were compared in subgroups classified
according to family history and age at diagnosis. Table 6
shows the genotype frequencies for the seven polymor-
phisms within subgroups of invasive breast cancer
(defined by tumour grade, nodal status and vascular inva-
sion). Figures 1, 2, 3, 4, 5, 6, 7, 8 show survival curves
demonstrating that none of the polymorphisms had any
impact on time to death or development of metastases in
those with invasive breast cancer.
Further analyses of the four polymorphisms in the Inter-
leukin-1 gene cluster (IL1A +4845G>T, IL1B +3954C>T,
IL1B -511C>T and IL1RN +2018T>C) were done using
Haploview. These four polymorphisms are situated a
region of size 360 kb. The LD (linkage disequilibrium)
values for the four pairs of SNPs (Figure 8) and the prob-
able haplotypes with their frequencies (Table 7) have
been calculated. None of the estimated haplotypes was
associated with breast cancer in this cohort.
The literature search demonstrated two previous studies
on the IL1B -511C>T polymorphism [57,58], one on the
IL1B +3954C>T polymorphism [58], six on the IL6 -
174G>C polymorphism Smith, 2004 #877} [58-62] and
four on the IL10 -1082G>A polymorphism [57,59,63,64].
The results of the previously published studies are dis-
cussed in the context of the results from the current study
in the next section.
Table 3: Cycling conditions for the PCRs for the different polymorphisms
Steps Time Temperature for the various SNPs
IL1A +4845 IL1B -511 IL1B +3954 IL1RN +2018 IL4R +1902 IL6 -174 IL10 -1082
1 2 minutes 50°C 50°C 50°C 50°C 50°C 50°C 50°C
2 10 minutes 95°C 95°C 95°C 95°C 95°C 95°C 95°C
3 15 seconds 95°C 95°C 95°C 95°C 95°C 95°C 95°C
41  m i n u t e s 59°C 59°C 61°C 64°C 61°C 62°C 62°C
5 40 times Go to step 3 Go to step 3 Go to step 3 Go to step 3 Go to step 3 Go to step 3 Go to step 3
6 Hold 15°C 15°C 15°C 15°C 15°C 15°C 15°CBMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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Discussion
Cytokines play varied roles in cancer pathogenesis with
increasing evidence suggesting their involvement in
tumour initiation, growth and metastasis [1]. Cytokine
gene polymorphisms have been studied for associations
with many inflammatory and neoplastic diseases. Numer-
ous reports have evaluated the association of individual
candidate SNPs in cytokine genes in breast cancer, some
of which are included in this study.
IL1A polymorphisms and breast cancer
IL1A is thought to contribute to breast cancer expression
by up-regulating pro-metastatic genes in breast cancer
cells and stromal cells [65]. IL1A levels in breast tissue
homogenates correlates inversely with ER levels [66],
which is an established prognostic marker in breast can-
cer. The IL1A gene is mapped to chromosome 2q13 and
includes several polymorphisms, of which one in the
5'UTR regulatory region (-889C>T) and one in exon 5 of
the gene (+4845G>T) have been commonly studied. The
IL1A -889 polymorphism has been studied in two differ-
ent cohorts and not shown to be associated with breast
cancer [58,67]. However, to date, there are no published
studies on the role of the IL1A +4845 polymorphism in
breast cancer. The current study has shown that there is a
trend for the rare allele to confer a protective effect against
cancer (p = 0.05) and for the common allele to be signifi-
cantly associated with lymph node positive cancers (p =
0.03). This effect is more apparent when the rare allele car-
riage rates (carriers of rare alleles) are assessed instead of
genotype frequencies (p = 0.005 and p = 0.007 respec-
tively). The positive finding however has not been subject
to corrections for multiple testing in view of the explora-
tory nature of these studies. In addition, given that the
genotype frequencies of this polymorphism were not in
Hardy Weinberg equilibrium, this may be an artefactual
association which would need confirmation in other pop-
ulations. There was no association of this polymorphism
with tumour grade, vessel invasion or survival.
IL1B polymorphisms and breast cancer
IL1β levels are high in breast cancer tissue and correlate
with invasiveness and an aggressive phenotype [68]. They
seem to regulate cancer cell proliferation through oestro-
gen production by steroid-catalyzing enzymes in the tis-
sue [69]. The IL1B gene is mapped to 2q13 [70] and the
commonly described genetic variants include the -
511C>T and the -31C>T in the 5'UTR and the +3954C>T
polymorphism in exon 5 of the gene. Our data for the -
511 and the +3954 SNPs show that overall; neither of
these SNPs is associated with breast cancer susceptibility,
severity or survival. As table 4c shows, in women with a
positive family history of breast cancer, the IL1B +3954T
allele was associated with a reduced risk of breast cancer.
The significance of this association on exploratory sub-
group analysis is however limited. Tables 8 and 9 show
data from two other studies confirming our findings that
these polymorphisms do play a significant role in breast
cancer susceptibility or severity.
IL1RN polymorphisms and breast cancer
It has been shown that IL1RA levels are increased in breast
cancer tissue and that IL1RA levels correlate with ER levels
[66]. At least 18 sequence variants exist around the IL1RN
gene [71] located in chromosome 2q13 [70]. Of these, the
penta-allelic variant in intron 2 and the +2018T>C have
been commonly studied. There are no prior reports of the
IL1RN +2018 polymorphism in breast cancer. The
intronic polymorphism described however has however
been studied in breast cancer without any significant asso-
Table 4: Observed and Expected genotype frequencies and the HardyWeinberg Equilibrium in the control population
SNP Controls 
(n)
Observed Genotype Frequency Allele Frequency
(in %)
Expected Genotype 
Frequency
Chi-square Goodness 
of fit test statistic (p 
value)
1:1 1:2 2:2 1 2 1:1 1:2 2:2 2:2
IL1A +4845 498 215 245 38 67.8 32.2 229 217 52 χ2 = 7.49;
p = 0.01
IL1B -511 489 232 206 51 66.5 31.5 230 211 48 χ2 = 0.20;
p = 0.66
IL1B +3954 420 231 167 22 74.9 25.1 235 158 27 χ2 = 1.13;
p = 0.29
IL1RN +2018 490 247 202 41 71 29 247 202 41 χ2 = 0;
p = 0.95
IL4R +1902 767 451 288 28 77.6 22.4 461 267 39 χ2 = 4.45;
p = 0.03
IL6 -174 490 168 235 87 58.3 41.7 167 238 85 χ2 = 0.06;
p = 0.81
IL10 -1082 498 117 260 121 49.6 50.4 123 249 126 χ2 = 0.85;
p = 0.36BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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Table 5: Genotype frequencies of the seven polymorphisms in subgroups of breast cancer and control populations
Subsets Case/control Genotype Frequencies (%) Chi square test for trend (p value)
1:1 1:2 2:2
IL1A +4845 G>T
Overall Cancers (n = 697) 360 (51.6%) 275 (39.5%) 62 (8.9%) X2 = 3.71; p = 0.05
Controls (n = 498) 215 (43.2%) 245 (49.2%) 38 (7.6%)
Positive Family History Cancers (n = 192) 106 (55.2%) 71 (37%) 15 (7.8%) X2 = 2.74; p = 0.10
Controls (n = 104) 44 (42.3%) 52 (50%) 8 (7.7%)
Negative Family History Cancers (n = 505) 254 (50.3%) 204 (40.4%) 47 (9.3%) X2 = 1.47; p = 0.23
Controls (n = 394) 171 (43.4%) 193 (49%) 30 (7.6%)
Young cancers vs. controls Cancers (n = 113) 55 (48.7%) 43 (38%) 15 (13.3%) X2 = 0; p = 0.98
Controls (n = 498) 215 (43.2%) 245 (49.2%) 38 (7.6%)
IL1B -511 C>T
Overall Cancers (n = 703) 339 (48.2%) 294 (41.8%) 70 (10%) X2 = 0.10; p = 0.75
Controls (n = 489) 232 (47.4%) 206 (42.1%) 51 (10.4%)
Positive Family History Cancers (n = 195) 96 (49.2%) 85 (43.6%) 14 (7.2%) X2 = 0.45; p = 0.51
Controls (n = 103) 48 (46.6%) 45 (43.7%) 10 (9.7%)
Negative Family History Cancers (n = 508) 243 (47.8%) 209 (41.1%) 56 (11%) X2 = 0.003; p = 0.96
Controls (n = 386) 184 (47.7%) 161 (41.7%) 41 (10.6%)
Young cancers vs. controls Cancers (n = 115) 55 (47.8%) 49 (42.6%) 11 (9.6%) X2 = 0.033; p = 0.86
Controls (n = 489) 232 (47.4%) 206 (42.1%) 51 (10.4%)
IL1B +3954 C>T
Overall Cancers (n = 691) 410 (59.3%) 242 (35%) 39 (5.6%) X2 = 1.12; p = 0.29
Controls (n = 420) 231 (55%) 167 (39.8%) 22 (5.2%)
Positive Family History Cancers (n = 193) 129 (66.8%) 55 (28.5%) 9 (4.7%) X2 = 8.75; p = 0.003*
Controls (n = 91) 43 (47.3%) 41 (45.1%) 7 (7.7%)
Negative Family History Cancers (n = 498) 281 (56.4%) 187 (37.6%) 30 (6%) X2 = 0.26; p = 0.61
Controls (n = 329) 188 (57.1%) 126 (38.3%) 15 (4.6%)
Young cancers vs. controls Cancers (n = 112) 64 (57.1%) 41 (36.6%) 7 (6.3%) X2 = 0.03; p = 0.86
Controls (n = 420) 231 (55%) 167 (39.8%) 22 (5.2%)
IL1RN +2018 T>C
Overall Cancers (n = 697) 349 (50.1%) 286 (41%) 62 (8.9%) X2 = 0.05; p = 0.82
Controls (n = 490) 247 (50.4%) 202 (41.2%) 41 (8.4%)
Positive Family History Cancers (n = 193) 94 (48.7%) 84 (43.5%) 15 (7.8%) X2 = 0.074; p = 0.79
Controls (n = 103) 48 (46.6%) 47 (45.6%) 8 (7.8%)
Negative Family History Cancers (n = 504) 255 (50.6%) 202 (40.1%) 47 (9.3%) X2 = 0.14; p = 0.71
Controls (n = 387) 199 (51.4%) 155 (40.1%) 33 (8.5%)
Young cancers vs. controls Cancers (n = 113) 61 (54%) 44 (38.9%) 8 (7.1%) X2 = 0.53; p = 0.47
Controls (n = 490) 247 (50.4%) 202 (41.2%) 41 (8.4%)
IL4R +1902 A>G
Overall Cancers (n = 775) 493 (63.6%) 249 (32.1%) 33 (4.3%) X2 = 2.1; p = 0.15
Controls (n = 767) 451 (58.8%) 288 (37.5%) 28 (3.7%)
Positive Family History Cancers (n = 212) 133 (62.7%) 70 (33%) 9 (4.2%) X2 = 0.19; p = 0.66
Controls (n = 168) 98 (58.3%) 66 (39.3%) 4 (2.4%)
Negative Family History Cancers (n = 563) 360 (63.9%) 179 (31.8%) 24 (4.3%) X2 = 2.00; p = 0.16
Controls (n = 599) 353 (58.9%) 222 (37.1%) 24 (4.0%)
Young cancers vs. controls Cancers (n = 122) 85 (69.7%) 36 (29.5%) 1 (0.8%) X2 = 6.36; p = 0.012*
Controls (n = 767) 451 (58.8%) 288 (37.5%) 28 (3.7%)
IL6 -174 G>CBMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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Overall Cancers (n = 497) 170 (34.2%) 244 (49.1%) 83 (16.7%) X2 = 0.05; p = 0.83
Controls (n = 490) 168 (34.3%) 235 (48%) 87 (17.8%)
Positive Family History Cancers (n = 127) 47 (37%) 55 (43.3%) 25(19.7%) X2 = 0.20; p = 0.66
Controls (n = 102) 38 (37.3%) 48 (47.1%) 16(15.7%)
Negative Family History Cancers (n = 370) 123 (33.2%) 189 (51.1%) 58 (15.7%) X2 = 1.22; p = 0.64
Controls (n = 388) 130 (33.5%) 187 (48.2%) 71 (18.3%)
Young cancers vs. controls Cancers (n = 85) 36 (42.4%) 31 (36.5%) 18 (21.2%) X2 = 0.31; p = 0.58
Controls (n = 490) 168 (34.3%) 235 (48%) 87 (17.8%)
IL10 -1082 G>A
Overall Cancers (n = 497) 121 (24.3%) 253 (50.9%) 123 (24.7%) X2 = 0.01; p = 0.93
Controls (n = 498) 117 (23.5%) 260 (52.2%) 121 (24.3%)
Positive Family History Cancers (n = 126) 31 (24.6%) 69 (54.8%) 26 (20.6%) X2 = 0.39; p = 0.54
Controls (n = 104) 31 (29.8%) 52 (50%) 21 (20.2%)
Negative Family History Cancers (n = 371) 90 (24.3%) 184 (49.6%) 97 (26.1%) X2 = 0.11; p = 0.74
Controls (n = 394) 86 (21.8%) 208 (52.8%) 100 (25.4%)
Young cancers vs. controls Cancers (n = 84) 17 (20.2%) 44 (52.4%) 23 (27.4%) X2 = 0.60; p = 0.44
Controls (n = 498) 117 (23.5%) 260 (52.2%) 121 (24.3%)
Note: Family history: either first or second degree relative with breast cancer. Young cancer patients: </=50 years of age
Table 5: Genotype frequencies of the seven polymorphisms in subgroups of breast cancer and control populations (Continued)
ciation with susceptibility or prognosis [58]. Our data
shows no association of the +2018T>C polymorphism
with breast cancer risk, severity or survival from the dis-
ease.
In addition to the analysis of the individual polymor-
phisms in the IL1A, IL1B and IL1RN genes, comparison of
the probable haplotype frequencies in the breast cancer
and control cohorts did not show any significant differ-
ences between the two groups.
IL4R polymorphisms and breast cancer
IL4 receptor is significantly expressed in breast cancer [72]
and it has been shown that IL4R is required for actions of
IL4 on breast cancer cells [12] including the inhibition of
growth and induction of apoptosis. The IL4R gene has
been localised to 16p12. Several coding and regulatory
region polymorphisms exist in the IL4R gene and are
thought to influence signal transduction on the IL4 signal-
ling pathway [73]. Our data on the IL4R polymorphism
+1902A>G has shown no overall association with breast
cancer susceptibility, severity or survival. In the subgroup
of young cancer patients (those </=50 years at diagnosis),
we found that the G allele was significantly associated
with breast cancer. There are no other studies of this pol-
ymorphism in breast cancer.
IL6 polymorphisms and breast cancer
The circulating level of interleukin 6 is thought to be ele-
vated in the development and progression of many
tumours including breast cancer and its up-regulation is
associated with invasiveness and increased metastatic
potential of ER negative tumours [74]. The IL6 gene has
been localised to chromosome 7p21. Although several
polymorphisms exist in the promoter region of IL-6 and
are thought to have a complex interactive effect on IL6
expression [75], the polymorphism at -174 has been most
extensively studied and shown to have significant ethnic
variation [74]. Table 10 shows the various studies of this
polymorphism in breast cancer to date. Only one study
demonstrated an association with breast cancer suscepti-
bility [58], which showed a significant Odds ratio of 1.5
and 2.0 for the heterozygotes (GC) and the rare homozy-
gotes (CC) when compared to the common homozygotes
(GG). The study however included a non-healthy control
population (women attending outpatient departments for
various reasons) and a lack of correction for multiple test-
ing. Our data shows that the IL6 -174G>C polymorphism
was not associated with either breast cancer risk or severity
and prognosis as assessed by tumour grade, lymph nodal
status, vascular invasion or survival.
IL10 polymorphisms and breast cancer
IL10 has been shown to have anti-metastatic and anti-
tumour effects in murine breast cancer models [17].
Mononuclear cells from breast cancer patients exhibit
increased IL10 production [76] and IL10 serum levels cor-
relate with stage of the disease [77]. Several single nucleo-
tide polymorphisms exist in the promoter region of the
IL10 gene (localised to chromosome 1q31-q32) including
-1082, -819 and -592 [78]. Table 11 shows the studies of
the IL10 -1082G>A polymorphism in breast cancer. Of
the three studies reported, only one suggests a role for the
G allele in reducing breast cancer risk [63]. Our data,
which includes larger numbers of individuals, however
shows no association with breast cancer susceptibility,BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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Table 6: Genotype frequencies of the seven polymorphisms in subgroups of invasive breast cancer.
Tumour Severity Subgroups Genotype frequencies (%) Chi square test for trend (P value)
1:1 1:2 2:2
IL1A +4845 G>T
Tumour Grade Grade 1 (n = 122) 62 (50.8%) 50 (41%) 10 (8.2%) X2 = 0.037; p = 0.85
Grade 2 (n = 283) 151 (53.4%) 109 (38.5%) 23 (8.1%)
Grade 3 (n = 216) 115 (53.2%) 82 (38%) 19 (8.8%)
Nodal Involvement Absent (n = 430) 204 (47.4%) 118 (43.7%) 38 (8.8%) X2 = 4.75; p = 0.03*
Present (n = 117) 117 (59.4%) 63 (32%) 17 (8.6%)
Vascular Invasion Absent (n = 467) 243 (52%) 185 (39.6%) 39 (8.4%) X2 = 0.058; p = 0.81
Present (n = 117) 64 (54.7%) 42 (35.9%) 11 (9.4%)
IL1B -511 C>T
Tumour Grade Grade 1 (n = 126) 51 (40.5%) 59 (46.8%) 16 (12.7%) X2 = 0.12; p = 0.73
Grade 2 (n = 284) 150 (52.8%) 111 (39.1%) 23 (8.1%)
Grade 3 (n = 216) 98 (45.4%) 93 (43.1%) 25 (11.6%)
Nodal Involvement Absent (n = 434) 214 (49.3%) 179 (41.2%) 41 (9.4%) X2 = 0.79; p = 0.37
Present (n = 198) 90 (45.5%) 87 (43.9%) 21 (10.6%)
Vascular Invasion Absent (n = 473) 224 (47.4%) 201 (42.5%) 48 (10.1%) X2 = 0.38; p = 0.54
Present (n = 116) 57 (49.1%) 50 (43.1%) 9 (7.8%)
IL1B +3954 C>T
Tumour Grade Grade 1 (n = 121) 68 (56.2%) 48 (39.7%) 5 (4.1%) X2 = 0.053; p = 0.82
Grade 2 (n = 279) 173 (62%) 90 (32.3%) 16 (5.7%)
Grade 3 (n = 215) 131 (60.9%) 70 (32.6%) 14 (6.5%)
Nodal Involvement Absent (n = 427) 244 (57.1%) 161 (37.7%) 22 (5.2%) X2 = 0.37; p = 0.54
Present (n = 194) 120 (61.9%) 61 (31.4%) 13 (6.7%)
Vascular Invasion Absent (n = 464) 283 (61%) 157 (33.8%) 24 (5.2%) X2 = 0.43; p = 0.51
Present (n = 114) 66 (57.9%) 41 (36%) 7 (6.1%)
IL1RN +2018 T>C
Tumour Grade Grade 1 (n = 125) 55 (44%) 55 (44%) 15 (12%) X2 = 0.73; p = 0.40
Grade 2 (n = 280) 150 (53.6%) 107 (38.2%) 23 (8.2%)
Grade 3 (n = 215) 108 (50.2%) 86 (40%) 21 (9.8%)
Nodal Involvement Absent (n = 429) 216 (50.3%) 180 (42%) 33 (7.7%) X2 = 0.11; p = 0.74
Present (n = 196) 102 (52%) 72 (36.7%) 22 (11.2%)
Vascular Invasion Absent (n = 463) 232 (50.1%) 191 (41.3%) 40 (8.6%) X2 = 1.34; p = 0.25
Present (n = 118) 67 (56.8%) 42 (35.6%) 9 (7.6%)
IL4R +1902 A>G
Tumour Grade Grade 1 (n = 137) 87 (63.5%) 44 (32.1%) 6 (4.4%) X2 = 0.14; p = 0.71
Grade 2 (n = 308) 195 (63.3%) 97 (31.5%) 16 (5.2%)
Grade 3 (n = 228) 146 (64%) 75 (32.9%) 7 (3.1%)
Nodal Involvement Absent (n = 477) 313 (65.6%) 144 (30.2%) 20 (4.2%) X2 = 0.11; p = 0.75
Present (n = 212) 135 (63.7%) 69 (32.5%) 8 (3.8%)
Vascular Invasion Absent (n = 508) 316 (62.2%) 170 (33.5%) 22 (4.3%) X2 = 0.002; p = 0.96
Present (n = 129) 82 (63.6%) 40 (31%) 7 (5.4%)
IL6 -174 G>C
Tumour Grade Grade 1 (n = 80) 26 (32.5%) 38 (47.5%) 16 (20%) X2 = 0.04; p = 0.84
Grade 2 (n = 204) 78 (38.2%) 95 (46.6%) 31 (15.2%)
Grade 3 (n = 159) 49 (30.8%) 83 (52.2%) 27 (17%)BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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Nodal Involvement Absent (n = 293) 100 (34.1%) 141 (48.1%) 52 (17.7%) X2 = 0.20; p = 0.66
Present (n = 143) 52 (36.4%) 67 (46.9%) 24 (16.8%)
Vascular Invasion Absent (n = 325) 112 (34.5%) 159 (48.9%) 54 (16.6%) X2 = 0.001; p = 0.98
Present (n = 85) 29 (34.1%) 42 (49.4%) 14 (16.5%)
IL10 -1082 G>A
Tumour Grade Grade 1 (n = 80) 23 (28.8%) 37 (46.3%) 20 (25%) X2 = 0.37; p = 0.54
Grade 2 (n = 205) 39 (19%) 113 (55.1%) 53 (25.9%)
Grade 3 (n = 158) 44 (27.8%) 79 (50%) 35 (22.2%)
Nodal Involvement Absent (n = 293) 69 (23.5%) 148 (50.5%) 76 (25.9%) X2 = 0.84; p = 0.36
Present (n = 143) 38 (26.6%) 73 (51%) 32 (22.4%)
Vascular Invasion Absent (n = 325) 87 (26.8%) 156 (48%) 82 (25.2%) X2 = 3.3; p = 0.07
Present (n = 85) 12 (14.1%) 49 (57.6%) 24 (28.2%)
Table 6: Genotype frequencies of the seven polymorphisms in subgroups of invasive breast cancer. (Continued)
severity or survival for this polymorphism. A study on the
related polymorphism (-592C>A) in the promoter region
was associated with a reduced breast cancer risk, although
in breast cancer patients, there was no association with
severity of the disease [79].
Limitations
Although our study had more than twice the number of
subjects than the similar studies on cytokine polymor-
phisms in breast cancer, it could still be argued that asso-
ciations of a minor degree (Odds Ratio < 1.5) of the
genetic markers studied or other related markers may have
been missed. For example, to detect a rare marker (of fre-
quency 10%) associated with a 1.3 times increased risk of
breast cancer (Odds Ratio = 1.3) with a power of 80% and
type I error of 0.5%, we would need a sample size of 2400
patients and controls. The second limitation is that a
small proportion of our control population would
develop breast cancer in their lifetime. However, it is gen-
erally considered difficult to obtain an ideal control
cohort for genetic epidemiologic studies in solid cancers
mainly due to the delayed onset of the disease. The prog-
nostic markers used for assessing breast cancer severity in
this study were limited to grade, lymph nodal status and
vascular invasion due to limited information available on
other indices such as hormone receptor status and tumour
size.
Conclusion
The results from our study do not support the hypothesis
that the cytokine polymorphisms studied [IL1A
+4845G>T, IL1B -511C>T, IL1B +3954C>T, IL1RN
+2018T>C, IL4R -1902A>G, IL6-174G>C and IL10-
1082G>A] are associated with breast cancer susceptibility
and severity. Minor influences and associations with sub-
groups of phenotypes may exist, but are unlikely to be of
any major clinical significance.
Abbreviations
IL: interleukin; ER: oestrogen receptor; SNP: single
nucleotide polymorphism; UTR: untranslated region;
PCR: polymerase chain reaction; DNA: deoxyribonucleic
acid.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SPB, IAFA and SEH carried out patient recruitment, the
molecular genetic studies and drafted the manuscript. SSC
reviewed the pathology and drafted the manuscript. SPB
and AC participated in the design of the study and per-
formed the statistical analysis. AGW, NJB and MWR con-
ceived of the study, and participated in its design and
coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We would like to thank Helen Cramp, Jane McDaid and Claire Greaves for 
help with recruitment and genotyping, Dan Connley for data management, 
and all the people who took part in the study. AC is funded by the York-
shire Cancer Research. We would also like to thank the Royal College of 
Surgeons of Edinburgh who provided financial assistance towards consum-
ables for this study.BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
Page 10 of 21
(page number not for citation purposes)
shows the time to death or metastases in invasive breast cancer for the genotypes of the IL1A +4845 polymorphism Figure 1
shows the time to death or metastases in invasive breast cancer for the genotypes of the IL1A +4845 polymorphism. Log Rank 
test statistic = 1.52; df = 2; p = 0.47 (n = 482).BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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shows the time to death or metastases in invasive breast cancer for the genotypes of the IL1B -511 polymorphism Figure 2
shows the time to death or metastases in invasive breast cancer for the genotypes of the IL1B -511 polymorphism. Log Rank 
test statistic = 5.07; df = 2; p = 0.08 (n = 484).BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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shows the time to death or metastases in invasive breast cancer for the genotypes of the IL1B +3954 polymorphism Figure 3
shows the time to death or metastases in invasive breast cancer for the genotypes of the IL1B +3954 polymorphism. Log Rank 
test statistic = 2.71; df = 2; p = 0.26 (n = 479).BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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shows the time to death or metastases in invasive breast cancer for the genotypes of the IL1RN +2018 polymorphism Figure 4
shows the time to death or metastases in invasive breast cancer for the genotypes of the IL1RN +2018 polymorphism. Log 
Rank test statistic = 4.32; df = 2; p = 0.12 (n = 481).BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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shows the time to death or metastases in invasive breast cancer for the genotypes of the IL4R +1902 polymorphism Figure 5
shows the time to death or metastases in invasive breast cancer for the genotypes of the IL4R +1902 polymorphism. Log Rank 
test statistic = 2.07; df = 2; p = 0.35 (n = 528).BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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shows the time to death or metastases in invasive breast cancer for the genotypes of the IL6 -174 polymorphism Figure 6
shows the time to death or metastases in invasive breast cancer for the genotypes of the IL6 -174 polymorphism. Log Rank test 
statistic = 0.16; df = 2; p = 0.92 (n = 333).BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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shows the time to death or metastases in invasive breast cancer for the genotypes of the IL10 -1082 polymorphism Figure 7
shows the time to death or metastases in invasive breast cancer for the genotypes of the IL10 -1082 polymorphism. Log Rank 
test statistic = 1.34; df = 2; p = 0.51 (n = 332).BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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Table 7: Probable frequencies of the common haplotypes in the interleukin-1 gene cluster in breast cancer and screening control 
cohorts.
Haplotype* Frequency Case, Control Ratios Chi-square P value
GCCT 0.330 471.5 : 938.5, 321.5 : 674.5 0.352 0.5529
TTCT 0.165 220.7 : 1189.3, 176.8 : 819.2 1.865 0.1720
GCTC 0.133 182.1 : 1227.9, 138.3 : 857.7 0.469 0.4934
GCTT 0.112 169.0 : 1241.0, 99.9 : 896.1 2.239 0.1346
GCCC 0.099 145.8 : 1264.2, 91.3 : 904.7 0.913 0.3392
TCCT 0.032 42.1 : 1367.9, 35.4 : 960.6 0.602 0.4376
TCTT 0.026 32.4 : 1377.6, 30.1 : 965.9 1.202 0.2729
GTCT 0.024 36.1 : 1373.9, 22.6 : 973.4 0.214 0.6440
TTCC 0.022 33.5 : 1376.5, 19.9 : 976.1 0.377 0.5394
TTTT 0.017 21.2 : 1388.8, 19.8 : 976.2 0.817 0.3661
TCCC 0.016 24.6 : 1385.4, 14.1 : 981.9 0.4 0.5271
TCTC 0.013 16.7 : 1393.3, 14.3 : 981.7 0.295 0.5873
* The haplotypes represent the four polymorphisms (IL1A +4845G>T, IL1B +3954C>T, IL1B -511C>T and IL1RN +2018T>C) in that order.
shows the linkage disequilibrium plot (obtained using Haplov- iew) showing pairwise D' values (in percentage) between the  four polymorphisms on chromosome 2q13 Figure 8
shows the linkage disequilibrium plot (obtained using Haplov-
iew) showing pairwise D' values (in percentage) between the 
four polymorphisms on chromosome 2q13. The markers 1, 
2, 3 and 4 are IL1A +4845G>T, IL1B +3954C>T, IL1B -511 
C>T and IL1RN +2018T>C respectively.BMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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Table 10: Studies of the IL6 -174G>C polymorphism in breast cancer.
Reference Numbers studied Type of controls Susceptibility Severity Ethnicity
Cancer Controls
Smith KC et al, 
2004 [57]
144 224 Bone marrow and solid organ 
donors – male and female
No association No association mixed
Hefler LA et al, 
2005 [58]
269 227 Women visiting outpatient 
dept for various reasons
OR = 1.5 (1.04–
2.3)* for GC vs. 
GG OR = 2 (1.1–
3.6)* for CC vs. 
GG
No association Caucasian
Skerrett DL et al, 
2005 [59]
88 102 Maternal cord blood samples No association No association mixed
Saha A et al, 2003 
[60]
26 95 Unknown No association Not studied Asian Indian
DeMichelle A et al, 
2003 [61]
80 0 - Not studied C allele associated with 4 
year disease free survival (p 
= 0.02) and overall survival 
(p = 0.01) in node positive 
patients
mixed
Iacopetta B et al, 
2004 [62]
256 0 - Not studied C allele associated with high 
grade (p = 0.04) and CC 
genotype associated with 
poor survival (p = 0.03)
mixed
Our study 497 490 Women with normal 
mammograms from screening 
population
No association No association British Caucasian
OR: Odds Ratio
Table 8: Studies of the IL1B -511C>T polymorphism in breast cancer.
Reference Numbers studied Type of controls Susceptibility Severity Ethnicity
Cancer Controls
Smith KC et al, 2004 [57] 141 261 Bone marrow and solid organ donors – 
male and female
No association No association mixed
Hefler LA et al, 2005 [58] 269 227 Women visiting outpatient dept for 
various reasons
No association No association Caucasian
Our study 703 489 Women with normal mammograms 
from screening population
No association No association British Caucasian
Table 9: Studies of the IL1B +3954C>T polymorphism in breast cancer.
Reference Numbers studied Type of controls Susceptibility Severity Ethnicity
Cancer Controls
Hefler LA et al, 2005 [58] 269 227 Women visiting outpatient dept for 
various reasons
No association No association Caucasian
Our study 691 420 Women with normal mammograms 
from screening population
No association No association British CaucasianBMC Cancer 2006, 6:188 http://www.biomedcentral.com/1471-2407/6/188
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